Sierra Oncology, Inc. (SRRA): Price and Financial Metrics
GET POWR RATINGS... FREE!
SRRA Stock Price Chart Interactive Chart >
SRRA Price/Volume Stats
| Current price | $54.99 | 52-week high | $55.19 |
| Prev. close | $54.97 | 52-week low | $14.91 |
| Day low | $54.98 | Volume | 862,800 |
| Day high | $55.17 | Avg. volume | 931,731 |
| 50-day MA | $54.73 | Dividend yield | N/A |
| 200-day MA | $33.52 | Market Cap | 1.34B |
Sierra Oncology, Inc. (SRRA) Company Bio
Sierra Oncology, Inc., formerly known as ProNAi Therapeutics, is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform. The company was founded in 2003 and is based in Vancouver, Canada.
Latest SRRA News From Around the Web
Below are the latest news stories about Sierra Oncology Inc that investors may wish to consider to help them evaluate SRRA as an investment opportunity.
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)SAN MATEO, Calif., February 18, 2022--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted a stock option to one new employee as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such in |
Harley-Davidson, SOC Telemed Stocks See Action From Activist InvestorsH Partners raised its investment in motorcycle giant Harley-Davidson. Warburg PIncus has a large stake in telemedecine firm SOC Telemed. |
Sierra Oncology raises additional funds from underwriters of stock offeringSierra Oncology (NASDAQ:SRRA) said the underwriters of its previously announced public offering exercised in full their option to buy an additional 750K common shares at $27 per share. With this exercise, the gross proceeds to Sierra were ~$155.3M. Sierra intends to use the net proceeds to prepare for potential commercialization of... |
Sierra Oncology Announces Full Exercise of Underwriters’ Option to Purchase Additional SharesSAN MATEO, Calif., February 03, 2022--Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced that the underwriters of its previously announced underwritten public offering exercised in full their option to purchase 750,000 additional shares of common stock at a price of $27.00 per share, before deducting underwriting discounts and commissions. With this exercise, the aggregate gross proceeds to Sie |
Sierra Oncology to Participate in Guggenheim Oncology ConferenceSAN MATEO, Calif., February 03, 2022--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 4th Annual Guggenheim Oncology Conference being held virtually from February 9 – 11, 2022. President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will participate in an analyst-moderated fireside chat on Thursday, February 10, 2022, at 12:00 pm ET. |
SRRA Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | 67.91% |
| 3-year | 333.68% |
| 5-year | -51.93% |
| YTD | N/A |
| 2022 | 0.00% |
| 2021 | 35.62% |
| 2020 | 17.04% |
| 2019 | -74.06% |
| 2018 | -64.61% |
Loading social stream, please wait...